G1 Therapeutics (GTHX) 10-Q2024 Q1 Quarterly report

Filed: 1 May 24, 4:17pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accomplished, Australia, Bangladesh, cancellation, delivery, description, digit, expansion, frequently, immaterial, India, indirectly, Indonesia, Israel, Korea, Lanka, Malaysia, modified, Myanmar, Pakistan, parenteral, Pepper, precisely, radioprotectant, rescue, Singapore, South, Sri, Thailand, transformational, Vietnam, Zealand

Removed: accelerate, acting, added, advanced, advantage, agent, ambulatory, American, anemia, anticipating, applied, arresting, ASCENT, automatic, avelumab, backbone, beneficial, billing, blood, bore, capitalization, care, checkpoint, clinically, closed, CMS, Coding, comparison, conditionally, conducted, confirm, consistent, covering, Cowen, criteria, deducting, demonstrate, depending, desert, design, diagnostic, diarrhea, document, Dongyuan, drew, endpoint, enhance, enhancing, ESMO, evolving, exceeded, extensive, extinguished, forecast, foundational, furnished, GC, globally, greatest, group, hazard, health, healthcare, hereof, hospital, identify, immunomodulation, important, improvement, inflamed, inform, initially, inpatient, issuer, Kaplan, led, locally, maintenance, manifest, maximize, meaningful, median, Medicaid, Medicare, medicine, Meier, microenvironment, minimizing, monitoring, mUC, multilineage, myelosuppressive, Nanjing, NCCN, neutropenia, NTAP, numerical, observe, observed, operational, outpatient, pathologic, percentage, permanent, permitted, physician, pivotal, Practice, preliminary, prescription, present, PRESERVE, preventive, proactive, Procedure, profile, Programmed, progression, protecting, published, qualified, randomized, ratio, registered, request, row, sacituzumab, seasoned, separate, separated, showed, showing, shown, standardize, statistical, stopping, submission, suggest, superior, supportive, surgery, therapeutic, topline, treat, twelve, underwriting, unlimited, unresectable, untreated, usage, validate, waived

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated GTHX transcripts

GTHX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of G1 Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Date: May 1, 2024						/s/ John E. Bailey, Jr.
						John E. Bailey, Jr.
						President and Chief Executive Officer
						(Principal Executive Officer)

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of G1 Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.